Filing Flows › Health Care › Coherus Oncology (CHRS)
Coherus Oncology (CHRS) earnings and revenue breakdown
Latest: Q2 2026 · 10-Q filed Aug 5, 2026 · Coherus Oncology (CHRS) Q2 2026 earnings results →
Q2 2026 Revenue up 40% year over year to $14.3M · 144¢ of every $1 of revenue lost · operating margin -226.0%
Coherus Oncology made $14.3M in Q2 2026 (+40% Y/Y): Toripalimab $13.6M, Other revenue $694K. Operating margin -226.0%, net loss $20.6M. See where every dollar goes — costs, profit and cash — as a Sankey from the 10-Q filed Aug 5, 2026.
Drawing the Sankey…
Open the interactive Sankey → click any line for what the company wrote about it, compare Y/Y and Q/Q, export as PNG or PDF
What changed this quarter
Revenue was $14.3M in Q2 2026, up 40% year over year and up 16% from the previous quarter. Toripalimab was the largest line at 95% of revenue. Toripalimab added $3.7M year over year (up 37%), 90% of the total change.
Operating costs exceeded revenue by $32.3M, an operating margin of -226.0%. Total costs fell 16% while revenue rose 40%. The fastest-growing cost line was Cost of revenue (+25%). The quarter ended with a net loss of $20.6M, narrower than the previous quarter's $38.3M loss.
Operating cash flow was −$62.1M. Non-cash charges added back $862K of depreciation and amortization and $2.6M of share-based compensation. Working capital and other items used $44.9M.
Quarterly history
| Quarter | Form | Filed | Revenue | Y/Y | Op. margin | Net earnings | Op. cash flow |
|---|---|---|---|---|---|---|---|
| Q2 2026 | 10-Q | Aug 5, 2026 | $14.3M | +40% | -226.0% | −$20.6M | −$62.1M |
| Q1 2026 | 10-Q | May 11, 2026 | $12.3M | +62% | -293.7% | −$38.3M | −$57.9M |
| Q4 2025 | 10-K | Mar 9, 2026 | $12.7M | +65% | -359.9% | −$37.6M | −$19.7M |
| Q3 2025 | 10-Q | Nov 6, 2025 | $11.6M | +91% | -383.1% | −$35.5M | −$46.3M |
| Q2 2025 | 10-Q | Aug 7, 2025 | $10.3M | -0.4% | -443.6% | $298M | −$46.6M |
| Q1 2025 | 10-Q | May 12, 2025 | $7.6M | +229% | -597.9% | −$56.6M | −$25.8M |
| Q4 2024 | 10-K | Mar 17, 2025 | $54.1M | -41% | -78.0% | −$50.7M | $28.6M |
Charts
Interactive views
The same charts as the app — open one to draw it.
💵Where each $1 goesinteractive
Loading the interactive chart…
🌏Named in Asian annual reportsinteractive
Loading the interactive chart…
🔄Rotation against the market and its industry (RRG)interactive
Loading the interactive chart…
🔍Earnings qualityinteractive
Loading the interactive chart…
⚖️Fair value by methodinteractive
Loading the interactive chart…
🔭Outlook & guidanceinteractive
Loading the interactive chart…
📈Investments: gains and what it boughtinteractive
Loading the interactive chart…
🏭Its industry’s money flow (input-output)interactive
Loading the interactive chart…
Customers and suppliers named in filings
Sells to
- MCK — 43% of its revenue · Stated in 10-K (XBRL) · source
- COR — 36% of its revenue · Stated in 10-K (XBRL) · source
- CAH — 20% of its revenue · Stated in 10-K (XBRL) · source
About Coherus Oncology
We are a fully integrated commercial-stage innovative oncology company with an approved next-generation programmed death receptor-1 (“PD-1”) inhibitor, LOQTORZI® (toripalimab-tpzi), and a pipeline that includes two mid-stage clinical candidates targeting liver, head and neck, colorectal and other cancers. Our strategy is to grow sales of LOQTORZI in nasopharyngeal carcinoma (“NPC”) and advance the development of new indications for LOQTORZI in combination with both our pipeline candidates as well as our partners, driving sales multiples and synergies from proprietary combinations. On May 29, 2025, we changed our corporate name from “Coherus BioSciences, Inc.” to “Coherus Oncology, Inc.” to better align with our exclusive focus on proprietary innovative immuno-oncology medicines following the completion of the recent divestitures of our biosimilar businesses.
In its own words, from its 10-K, filed Mar 9, 2026.
Coherus Oncology against its Biological Products, (No Diagnostic Substances) peers
The largest companies of the same SEC industry, each at its latest quarter. Revenue growth: +40% against the peers' median +29%. Operating margin: -226.0% against the peers' median 35.8%.
| Company | Quarter | Revenue | Y/Y | Op. margin |
|---|---|---|---|---|
| CHRS Coherus Oncology | Q2 2026 | $14.3M | +40% | -226.0% |
| AMGN Amgen | Q3 2026 | $10.4B | +8% | 35.8% |
| GILD Gilead Sciences | Q3 2026 | $8.3B | +7% | 41.7% |
| BIIB Biogen | Q3 2026 | $2.8B | +11% | -0.3% |
| MRNA Moderna | Q3 2026 | $1.3B | +29% | 9.9% |
| NBIX Neurocrine Biosciences | Q3 2026 | $1.1B | +41% | 29.5% |
| EXEL Exelixis | Q3 2026 | $659M | +10% | 40.8% |
| HALO Halozyme Therapeutics | Q3 2026 | $493M | +39% | 59.8% |
| MGTX MeiraGTx Holdings | Q2 2026 | $321M | 87× | 76.0% |
Source: Coherus Oncology 10-Q on SEC EDGAR · CIK 1512762 · Biological Products, (No Diagnostic Substances)
13F: who owns CHRS and who is buying
More on CHRS
History
Every quarter: Q2 2026 results · Q1 2026 results · Q4 2025 results · Q3 2025 results · Q2 2025 results · Q1 2025 results · Q4 2024 results